$MEDP — HOLD 📊

$MEDP — HOLD 📊 Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. 🎯 Q1 FY26 | Rev $1B | EPS $4.28 vs $3.96 🟢 💡 Consensus expected Q1 EPS of $3.96 and likely ~$16‑17 for FY2026. The beat suggests FY EPS could reach $17.50‑18.00, which at the current price implies a forward P/E of ~26‑27x — a slight premium to the peer median of 22‑25x. The market is already pricing continued double‑digit growth and best‑in‑class execution. 📉 Reward/Risk: 1.33:1 🏢 Business Quality: 8/10 - Medpace is a high‑quality, full‑service clinical CRO with deep relationships among small/mid‑sized biotechs, a strong reputation for reliability, and a sticky customer base. Margins are best‑in‑class, and the balance sheet is robust. 📊 Our read: HOLD. Full analysis → https://stockduty.xyz/s/MEDP0620

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.